Clinical Trial Update: A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. [Phase 1]

View source ↗

Summary

Phase 1 study of PF-07826390 in cancer patients, including non-small cell lung cancer, was terminated; the trial evaluated different doses of the medicine alone…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Carcinoma
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• PF-07826390 (PF-07826390)

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Status: TERMINATED